Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
18 Years to 55 Years
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:completedIn |
October 2022
|
| gptkbp:condition |
gptkb:Multiple_Sclerosis
|
| gptkbp:enrollment |
946
|
| gptkbp:gender |
All
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT03768413
|
| gptkbp:intervention |
gptkb:Ofatumumab
Parallel Assignment Teriflunomide |
| gptkbp:location |
gptkb:Canada
gptkb:France gptkb:Germany gptkb:Italy gptkb:Spain gptkb:United_States |
| gptkbp:mask |
Double
|
| gptkbp:officialName |
A Study of Ofatumumab Compared With Teriflunomide in Participants With Relapsing Multiple Sclerosis
|
| gptkbp:purpose |
Treatment
|
| gptkbp:recognizedBy |
gptkb:NCT03768413
|
| gptkbp:result |
Annualized relapse rate
|
| gptkbp:secondaryOutcome |
Confirmed disability worsening
|
| gptkbp:sponsor |
Novartis Pharmaceuticals
|
| gptkbp:startDate |
December 2018
|
| gptkbp:status |
Completed
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:NUC-7738
|
| gptkbp:bfsLayer |
8
|